Compare DexCom, Inc. (DXCM) vs Manhattan Associates Inc (MANH) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

MANH trades at $156.66, down 1.22% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust profitability with 56% gross margins and 19.68% net income margins, though valuations appear elevated with a P/E of 43.85. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.24 surpassing the $1.10 estimate. However, ongoing legal investigations into fiduciary duties create investor uncertainty.

The outlook remains positive with analyst consensus at Buy (73%) and a $192.80 price target suggesting 23% upside. Key risks include high valuation multiples, legal investigations, and potential execution challenges in cloud transition. Earnings growth and AI initiatives provide catalysts, but investors should weigh premium valuation against legal overhang.